Santiago Uranga
Overview
Explore the profile of Santiago Uranga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
482
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Aguilo N, Uranga S, Mata E, Tarancon R, Gomez A, Marinova D, et al.
Front Microbiol
. 2020 Jul;
11:1339.
PMID: 32625195
Vaccination through the natural route of infection represents an attractive immunization strategy in vaccinology. In the case of tuberculosis, vaccine delivery by the respiratory route has regained interest in recent...
12.
Perez I, Uranga S, Sayes F, Frigui W, Samper S, Arbues A, et al.
EBioMedicine
. 2020 May;
55:102761.
PMID: 32361249
Background: Human tuberculosis (TB) is caused by a plethora of Mycobacterium tuberculosis complex (MTBC) strains belonging to seven phylogenetic branches. Lineages 2, 3 and 4 are considered "modern" branches of...
13.
Tarancon R, Dominguez-Andres J, Uranga S, Ferreira A, Groh L, Domenech M, et al.
PLoS Pathog
. 2020 Apr;
16(4):e1008404.
PMID: 32240273
Among infectious diseases, tuberculosis is the leading cause of death worldwide, and represents a serious threat, especially in developing countries. The protective effects of Bacillus Calmette-Guerin (BCG), the current vaccine...
14.
Tarancon R, Uranga S, Martin C, Aguilo N
Allergy
. 2019 May;
74(12):2512-2514.
PMID: 31116888
No abstract available.
15.
Broset E, Saubi N, Guitart N, Aguilo N, Uranga S, Kilpelainen A, et al.
Mol Ther Methods Clin Dev
. 2019 Mar;
13:253-264.
PMID: 30859110
The tuberculosis (TB) vaccine MTBVAC is the only live-attenuated ()-based vaccine in clinical development, and it confers superior protection in different animal models compared to the current vaccine, BCG (...
16.
Alvarez-Arguedas S, Uranga S, Martin M, Elizalde J, Gomez A, Julian E, et al.
Transl Res
. 2018 Apr;
197:32-42.
PMID: 29702078
Intravesical instillation of bacillus Calmette-Guérin (BCG) has been a first-line therapy for non-muscle-invasive bladder cancer for the last 4 decades. However, this treatment causes serious adverse events in a significant...
17.
Gonzalo-Asensio J, Perez I, Aguilo N, Uranga S, Pico A, Lampreave C, et al.
PLoS Genet
. 2018 Apr;
14(4):e1007282.
PMID: 29649213
The insertion Sequence IS6110, only present in the pathogens of the Mycobacterium tuberculosis Complex (MTBC), has been the gold-standard epidemiological marker for TB for more than 25 years, but biological...
18.
Aguilo N, Gonzalo-Asensio J, Alvarez-Arguedas S, Marinova D, Gomez A, Uranga S, et al.
Nat Commun
. 2017 Jul;
8:16085.
PMID: 28706226
MTBVAC is a live-attenuated Mycobacterium tuberculosis vaccine, currently under clinical development, that contains the major antigens ESAT6 and CFP10. These antigens are absent from the current tuberculosis vaccine, BCG. Here...
19.
Uranga S, Marinova D, Martin C, Aguilo N
J Vis Exp
. 2016 Sep;
(115).
PMID: 27684521
Despite global coverage of intradermal BCG vaccination, tuberculosis remains one of the most prevalent infectious diseases in the world. Preclinical data have encouraged pulmonary tuberculosis vaccines as a promising strategy...
20.
Uranga S, Marinova D, Martin C, Pardo J, Aguilo N
PLoS One
. 2016 Apr;
11(4):e0153028.
PMID: 27055232
Granzyme A, a serine protease expressed in the granules of cytotoxic T and Natural Killer cells, is involved in the generation of pro-inflammatory cytokines by macrophages. Granzyme A has been...